Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
Allogene Q2 Cash Tops $300 Million
Allogene Therapeutics ( NASDAQ:ALLO ) reported second-quarter 2025 results on August 13, 2025, highlighting $302.6 million in cash and investments as of the end of Q2 2025 with a projected cash runway into the second half of 2027 despite reporting a GAAP net loss of $50.9 million.
Allogene Narrows Loss in Fiscal Q2
Allogene Therapeutics ( NASDAQ:ALLO ) , a biotechnology company developing off-the-shelf cell therapies for cancer and autoimmune diseases, reported its second quarter 2025 results on August 13, 2025. The release highlighted a smaller-than-expected GAAP net loss for Q2 2025. as the company ...
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update - Allogene Therapeutics ( NASDAQ:ALLO )
Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc.
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced that it will report the ...
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
NEW YORK, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Cellectis ( the "Company" ) ( Euronext Growth: ALCLS - NASDAQ: CLLS ) , a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the second ...
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Allogene Therapeutics ( NASDAQ:ALLO ) , AvalonBay Communities ( NYSE:AVB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Brian Cheng downgraded the rating for Allogene Therapeutics, Inc.
Allogene Resets Clinical Course After Patient Death In Lymphoma Study - Allogene Therapeutics ( NASDAQ:ALLO )
Allogene halts the ALLO-647 arm in the ALPHA3 trial after a patient's death is linked to a viral infection. Cema-cel will now be evaluated with standard FC only; next data due in first half of 2026. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide ( FC ) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel ( Cema-Cel ) in First-Line Consolidation for Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced that it has selected ...
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
CAR T-Cell Therapy Market to Surge at 40.2% CAGR Over the Next Five Years
Boston, July 10, 2025 ( GLOBE NEWSWIRE ) -- According to the latest study from BCC Research, the "Current R&D Status of Chimeric Antigen Receptor ( CAR ) T-Cell Therapy Market" is expected to grow from $4.6 billion in 2024 to $25.1 billion by the end of 2029, at a compound annual growth rate ( ...
Why Is Allogene Therapeutics ( ALLO ) Up 52.2% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
All You Need to Know About Allogene Therapeutics ( ALLO ) Rating Upgrade to Buy
Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
SOUTH SAN FRANCISCO, Calif., June 01, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, presented updated data from the Phase 1 ...
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - Allogene Therapeutics ( NASDAQ:ALLO )
SOUTH SAN FRANCISCO, Calif., May 23, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced that it will participate in four ...
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - Allogene Therapeutics ( NASDAQ:ALLO )
SOUTH SAN FRANCISCO, Calif., May 22, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc.
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
SOUTH SAN FRANCISCO, Calif., May 22, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced the publication of two ...
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.
Allogene Therapeutics ( ALLO ) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the ...
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - Allogene Therapeutics ( NASDAQ:ALLO )
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc.
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology ( ASCO ) Annual Meeting - Allogene Therapeutics ( NASDAQ:ALLO )
SOUTH SAN FRANCISCO, Calif., April 23, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc.
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology ( ASCO ) Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 23, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced that it will present ...
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
Adherex Technologies Inc. ( FENC ) Reports Q4 Loss, Misses Revenue Estimates
Adherex Technologies (FENC) delivered earnings and revenue surprises of -110.71% and 73.17%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
SOUTH SAN FRANCISCO, Calif., March 03, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced that it will report ...
Rhythm Pharmaceuticals, Inc. ( RYTM ) Reports Q4 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -4.35% and 2.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced an expanded strategic ...
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday - Allogene Therapeutics ( NASDAQ:ALLO ) , GCL Global Holdings ( NASDAQ:GCL )
U.S. stocks were lower, with the Dow Jones falling around 100 points on Tuesday. Shares of Watsco Inc WSO rose sharply during Tuesday's session after the company reported better-than-expected fourth-quarter EPS and revenue.
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced the publication of data ...
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases
The FDA clears ALLO's investigational new drug application to start clinical studies on its investigational CAR T product, ALLO-329, for autoimmune diseases.
Foresight Diagnostics Provides 2025 Outlook and 2024 Year in Review
- Achieved 100% revenue growth versus prior year - - Received Investigational Device Exemption approval from the FDA for the use of Foresight CLARITY™ for patient enrollment in the ALPHA3 clinical trial -
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.
Allogene Therapeutics ( ALLO ) Upgraded to Buy: What Does It Mean for the Stock?
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Allogene Therapeutics ( NASDAQ:ALLO )
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc.
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today acknowledged the passing of ...
PCRX Receives New Patent for Lead Pain Drug Exparel in the US
The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?
The dip in ALLO's share price can be attributed to strategic changes in its pipeline, which delayed bringing its lead drug to market by at least two years.
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.
APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA
Applied Therapeutics stock plummets 77% after the FDA issues a CRL for the company's NDA seeking approval for govorestat to treat classic galactosemia.
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.
